Cologne University Hospital (UKK), University of Marburg (UMR), the German Center for Infection Research (DZIF) and Boehringer Ingelheim today announced the initiation of Phase 1/2a clinical investigation of
COVID-19 (coronavirus) patients who were administered a novel antibody had fewer symptoms and were less likely to require hospitalization or emergency medical care than those who did not
THURSDAY, Oct. 29, 2020 — An Eli Lilly-developed COVID-19 antibody drug that didn’t help hospitalized patients might still prove effective in treating people with mild or moderate infections,
Eli Lilly ends paused trial of antibody drug and remdesivir after the NIH found the combo failed to help recovery of hospitalized patients Eli Lilly & Co and
Researchers with the U.S. Army Futures Command are part of a team that tested alternative ways to measure COVID-19 antibody levels, resulting in a process that is faster,
WEDNESDAY, Oct. 7, 2020 — Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19. The request to the U.S.
Nearly two million “rapid” antibody tests imported into Australia have been declared useless for determining whether someone has been exposed to the COVID-19 coronavirus. Testing by the Doherty
A Belgian biotech firm has started producing tests to rapidly detect antibodies against coronavirus infections, part of a push several countries are making to determine who might be
In this Oncotarget study, the authors test a novel anti-CEACAM antibody conjugated to a fluorescent dye for detection of multiple CEACAM antigens to enhance visualization of colorectal PDOX
For the first time, scientists have shown that in certain people living with HIV, a type of antibody called immunoglobulin G3 (IgG3) stops the immune system’s B cells
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
